List view / Grid view
BlueSphere Bio's TCXpress platform revolutionises the isolation and functional characterisation of T-cell receptors (TCRs) with unparalleled speed and efficiency, enabling rapid identification of unique TCRs from thousands of individual T cells within days.
The combination of two drugs was more effective in eradicating leukaemia cells in zebrafish and human disease than using a single drug.
A team have found that two DNA changes appear to predict acute lymphoblastic leukaemia, illuminating genetic understanding of the disease.
The study evaluating Down syndrome endothelial cells presented novel drug targets for leukaemia and suggested why DS patients may be at greater risk from the cancer.
A new CAR T-cell therapy has been created by researchers which targets three proteins on leukaemia cells and has shown success in pre-clinical trials.
The mechanism that prevents destruction of cancer cells by CAR T-cell therapy has been identified by researchers in Pennsylvania.
